Previous close | 107.66 |
Open | 107.00 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's range | 108.57 - 108.65 |
52-week range | 93.36 - 115.80 |
Volume | |
Avg. volume | 83,783 |
Market cap | N/A |
Beta (5Y monthly) | 0.74 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 18 Jul 2024 - 22 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.
Key Insights Abbott Laboratories to hold its Annual General Meeting on 26th of April Total pay for CEO Robert Ford...
Abbott Laboratories ( NYSE:ABT ) shareholders are probably feeling a little disappointed, since its shares fell 5.5% to...